USA - NASDAQ:MBIO - US62818Q3020 - Common Stock
We assign a fundamental rating of 2 out of 10 to MBIO. MBIO was compared to 534 industry peers in the Biotechnology industry. While MBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. MBIO does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.12% | ||
| ROE | -113.31% | ||
| ROIC | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -42.42 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.3 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
NASDAQ:MBIO (10/31/2025, 1:12:10 PM)
1.45
-0.01 (-0.68%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.63 | ||
| P/tB | 3.63 | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.12% | ||
| ROE | -113.31% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 1.3 | ||
| Altman-Z | -42.42 | 
ChartMill assigns a fundamental rating of 2 / 10 to MBIO.
ChartMill assigns a valuation rating of 1 / 10 to MUSTANG BIO INC (MBIO). This can be considered as Overvalued.
MUSTANG BIO INC (MBIO) has a profitability rating of 1 / 10.
The Earnings per Share (EPS) of MUSTANG BIO INC (MBIO) is expected to grow by 42.62% in the next year.